Table 3 Cumulative number of SARS-CoV-2 infections in the counterfactual booster scenario
Age group (years) | Booster immunization coveragea | Averted cases (95% confidence interval) | Relative change (%)b |
|---|---|---|---|
0–9 | Equiv. to 2nd dose | 617,501 (610,330–624,323) | -16.0 |
Equiv. to 4th dose | 983,421 (976,418–990,687) | 33.8 | |
Elevated coverage | 690,576 (684,180–696,569) | -6.0 | |
10–19 | Equiv. to 2nd dose | 477,638 (471,417–483,874) | -18.4 |
Equiv. to 4th dose | 800,801 (793,776–807,502) | 36.8 | |
Elevated coverage | 540,508 (534,463–545,744) | -7.7 | |
20–29 | Equiv. to 2nd dose | 684,634 (674,962–693,891) | -22.2 |
Equiv. to 4th dose | 1,344,003 (1,331,788–1,355,746) | 52.8 | |
Elevated coverage | 799,613 (791,240–806,938) | -9.1 | |
30–39 | Equiv. to 2nd dose | 636,277 (627,136–644,993) | -22.1 |
Equiv. to 4th dose | 1,305,604 (1,293,596–1,317,961) | 59.9 | |
Elevated coverage | 747,156 (739,796–754,618) | -8.5 | |
40–49 | Equiv. to 2nd dose | 608,320 (599,168–616,867) | -19.5 |
Equiv. to 4th dose | 1,182,119 (1,171,865–1,192,611) | 56.4 | |
Elevated coverage | 699,952 (691,723–707,332) | -7.4 | |
50–59 | Equiv. to 2nd dose | 351,601 (345,798–3,56,991) | -18.3 |
Equiv. to 4th dose | 714,765 (708,054–721,741) | 66.1 | |
Elevated coverage | 412,497 (407,216–417,354) | -4.1 | |
60–69 | Equiv. to 2nd dose | 164,808 (161,818–167,873) | -15.9 |
Equiv. to 4th dose | 340,978 (337,381–344,436) | 74.0 | |
Elevated coverage | 190,917 (188,132–193,644) | -2.6 | |
70–79 | Equiv. to 2nd dose | 111,101 (108,918–113,236) | -14.9 |
Equiv. to 4th dose | 196,119 (194,075–198,270) | 50.3 | |
Elevated coverage | 127,683 (125,583–129,707) | -2.2 | |
≥80 | Equiv. to 2nd dose | 108,193 (106,109–110,355) | -13.8 |
Equiv. to 4th dose | 217,011 (214,658–219,338) | 72.9 | |
Elevated coverage | 125,068 (123,036–127,109) | -0.3 |